Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Targeted delivery of antisense-mediated exon skipping therapy in a DMD transgenic pig model
EF 2014-15
Résumé
Duchenne muscular dystrophy (DMD), characterized by loss of muscle function, is one of the most common and deadly genetic disorders worldwide caused by mutations or alterations in the DMD gene. Currently, exon skipping therapy is one of the most promising therapeutic options for DMD patients. Exon skipping uses short DNA-like molecules, similar to "Band-Aids", to target the mutated or altered part of the gene. However, current clinical trials using exon skipping face three major challenges; 1) limited usefulness in the heart, 2) limited applicability (only 10% of DMD patients can be treated), 3) unknown stability and function of resulting proteins produced by the DNA Band-Aids. We have developed novel DNA-like molecules that efficiently target both skeletal muscle and heart. As well we have developed a cocktail of DNA Band-Aids that are applicable to majority of DMD patients with deletion mutations. This cocktail targets the mutation hotspot between exons 45 and 55 in the DMD gene, and could treat over 60% of human DMD causing mutations. This cocktail induces skipping of the entire exons 45-55 region. Spontaneous deletions of this specific region are associated with remarkably mild symptoms or normal individuals. Therefore, this strategy can potentially treat more than 60% of DMD deletion population, and also aim to provide near curative therapy. We have developed a novel transgenic pig model of DMD to test exon skipping strategies with DNA Band-Aids. This novel pig model with exon 52 deletion shows severe symptoms and is ideal for testing exons 45-55 skipping therapy. Using this pig model, the efficacy and safety of these novel molecules will be tested to ensure safety and applicability for novel clinical trials for DMD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331579
Name
Guncay Ashley
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted delivery of antisense-mediated exon skipping therapy in a DMD transgenic pig model
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antisense; Cell-Penetrating Peptides; Duchenne Muscular Dystrophy; Exon Skipping; In Vivo; Therapy
Abstract
Duchenne muscular dystrophy (DMD), characterized by loss of muscle function, is one of the most common and deadly genetic disorders worldwide caused by mutations or alterations in the DMD gene. Currently, exon skipping therapy is one of the most promising therapeutic options for DMD patients. Exon skipping uses short DNA-like molecules, similar to "Band-Aids", to target the mutated or altered part of the gene. However, current clinical trials using exon skipping face three major challenges; 1) limited usefulness in the heart, 2) limited applicability (only 10% of DMD patients can be treated), 3) unknown stability and function of resulting proteins produced by the DNA Band-Aids. We have developed novel DNA-like molecules that efficiently target both skeletal muscle and heart. As well we have developed a cocktail of DNA Band-Aids that are applicable to majority of DMD patients with deletion mutations. This cocktail targets the mutation hotspot between exons 45 and 55 in the DMD gene, and could treat over 60% of human DMD causing mutations. This cocktail induces skipping of the entire exons 45-55 region. Spontaneous deletions of this specific region are associated with remarkably mild symptoms or normal individuals. Therefore, this strategy can potentially treat more than 60% of DMD deletion population, and also aim to provide near curative therapy. We have developed a novel transgenic pig model of DMD to test exon skipping strategies with DNA Band-Aids. This novel pig model with exon 52 deletion shows severe symptoms and is ideal for testing exons 45-55 skipping therapy. Using this pig model, the efficacy and safety of these novel molecules will be tested to ensure safety and applicability for novel clinical trials for DMD.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Guncay, Ashley
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~